Fig. 2: CBD treatment (100 mg/kg) extends lifespan, reduces seizures, and ameliorates associated comorbidities in a MD-fatal epilepsy mouse model.
From: Cannabidiol ameliorates mitochondrial disease via PPARγ activation in preclinical models
a Kaplan–Meier survival curve of Gad2:Ndufs4cKO mice treated daily with vehicle (n = 24, gray) and CBD (n = 18, red, Log-rank test ****p < 0.0001), and control mice (n = 20, black). b % of Gad2:Ndufs4cKO mice acutely treated with vehicle (n = 5) or CBD (100 mg/kg, n = 7) upon thermally induced seizure onset that survived for the next 8 h. c % of Gad2:Ndufs4cKO mice acutely treated with vehicle (n = 5) or CBD (100 mg/kg, n = 5) 1 h before thermally inducing seizures that displayed (gray) or not (white) tonic-clonic seizures at some point during the next 4 h after seizure onset. Discrimination index of the time exploring a stranger mouse over an empty wire cage (d) and total exploration time (e) in the 3-chamber social interaction test of Gad2:Ndufs4cKO and control mice treated daily with vehicle or CBD (n = 12 [control-vehicle and Gad2:Ndufs4cKO-CBD], 16 [control-CBD and Gad2:Ndufs4cKO-vehicle], two-way ANOVA followed by Tukey’s multiple comparisons test, ****p < 0.0001 [genotype effect]; ####p < 0.0001 [treatment effect]). % of time spent in open arms (f), % of entries in open arms (g), and total arm entries (h) in the elevated plus maze test of Gad2:Ndufs4cKO and control mice treated daily with vehicle or CBD (n = 15 [control-vehicle], 22 [Gad2:Ndufs4cKO-vehicle], 13 [control-CBD], 11 [Gad2:Ndufs4cKO-CBD], two-way ANOVA followed by Tukey’s multiple comparisons test, ****p < 0.0001 [genotype effect]; ##p = 0.0055, ####p < 0.0001 [treatment effect]). All data are presented as mean values ± SEM. All source data are provided as a source data file. Veh vehicle, CT control mice, cKO Gad2:Ndufs4cKO mice.
